[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gallstones\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gallstones":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,81,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100629908","teas-combined-with-triple-antiemetic-drugs-to-prevent-ponv-in-high-risk-patients-100629908",false,"NCT07480785","TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients","Transcutaneous Electrical Acupoint Stimulation Combined With Triple Antiemetic Drugs for Postoperative Nausea and Vomiting in High-Risk Patients: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Women scheduled for laparoscopic surgery ；\n* Aged 18-65 years；\n* ASA Class I-III；\n* Apfel score ≥ 3 (female sex, non-smoker, history of PONV and\u002For motion sickness).\n\nExclusion Criteria:\n\n* Patients with a history of allergy to the investigational drug or contraindications；\n* Long-QT syndrome ；\n* Pregnancy, lactation, or menstruation ；\n* Current smoker；\n* Nausea\u002Fvomiting or use of antiemetics, opioids, or systemic corticosteroids within 24 h before surgery；\n* Requirement for post-operative sedation and mechanical ventilation ；\n* Severe renal or hepatic impairment ；\n* Psychiatric or neurological disorder ；\n* Vertebrobasilar insufficiency；\n* Vestibular disease；\n* Language or communication barrier ；\n* Skin lesion or infection at the acupoint stimulation site ；\n* Upper-limb nerve injury ；\n* Implanted cardiac pacemaker or defibrillator ；\n* Participation in another clinical trial within the past 4 weeks.","FEMALE","18 Years","65 Years",{"count":20,"type":21},780,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate the effects of transcutaneous electrical acupoint stimulation (TEAS) combined with triple antiemetics for postoperative nausea and vomiting (PONV) in high-risk patients.\n\nThe primary question it seeks to answer is:\n\nDoes TEAS combined with triple antiemetics further reduce the incidence of PONV in high-risk subjects? Researchers will compare active TEAS with sham stimulation to determine whether the addition of TEAS to dexamethasone, palonosetron, and droperidol lowers the PONV rate beyond that achieved by the triple-drug prophylaxis alone.",[27,28,29],"Uterine Fibroids (Leiomyoma)","Ovarian Tumors","Gallstones",[31,32,33],"postoperative nausea and vomiting","transcutaneous electrical acupoint stimulation","high-risk patients with PONV","RECRUITING","2026-03-15",{"date":37,"type":38},"2026-03-18","ACTUAL",{"date":40,"type":38},"2026-01-16",{"date":42,"type":21},"2027-10-31",{"name":44,"class":45},"Zhejiang University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":46},"100602107","surgical-techniques-robotic-versus-conventional-laparoscopic-cholecystectomy-in-benign-gallbladder-disease-100602107","NCT07119203","Surgical Techniques: Robotic Versus Conventional Laparoscopic Cholecystectomy IN Benign Gallbladder Disease","Surgical Techniques: Robotic Versus Conventional Laparoscopic Cholecystectomy IN Benign Gallbladder Disease: A Randomized Controlled, Open, Parallel, Non-inferiority, Single-center Trial (STaRLING Trial)","STaRLING","Inclusion Criteria:\n\n* Age equal or above 18 years;\n* Benign gallbladder disease: diagnosis of gallbladder polyps or symptomatic gallstones proven on imaging (ultrasound, computed tomography (CT) scan or magnetic resonance cholangiopancreatography (MRCP));\n* Capacity to give informed consent.\n\nExclusion Criteria:\n\n* Minimally invasive procedure is not deemed possible by the operating surgeon;\n* Evidence of acute cholecystitis;\n* Known stones in the common bile duct (CBD);\n* Suspicion of possible malignancy;\n* Pregnancy;\n* Diagnosis of liver cirrhosis (stage III or IV);\n* Insufficient language skills to be able to perform the quality-of-life questionnaires.","ALL",{"count":57,"type":21},276,[24],"This is a single-center, randomized controlled, parallel, non-inferiority trial. All adult patients with benign gallbladder disease with an indication for cholecystectomy will be assessed for eligibility and included after obtaining informed consent. A total of 276 patients will be randomized to undergo either robotic cholecystectomy (RC) or laparoscopic cholecystectomy (LC). The primary endpoint will be the incidence and severity of postoperative complications within 30 days after surgery. Secondary endpoints include perioperative outcomes, total health care utilization, health-related quality of life (HR-QoL) as assessed by patient-reported outcome measures, and cost-effectiveness. Follow-up assessments will be conducted at 7 and 30 days postoperatively.\n\nThis is the first randomized controlled trial designed to compare RC with LC in the treatment of benign gallbladder disease. The trial aims to evaluate the safety and non-inferiority of RC relative to LC, providing important evidence to guide the progress and adoption of robotic surgery in clinical practice.",[61,62,63,29,64],"Cholecystectomy, Robotic","Cholecystectomy, Laparoscopic","Cholecystectomy","Benign Gallbladder Disease",[66,67,68,69,70],"Robotic cholecystectomy","Laparoscopic cholecystectomy","Benign gallbladder disease","Randomized controlled trial","Cost-effectiveness","2025-12-16",{"date":73,"type":38},"2025-12-23",{"date":75,"type":38},"2025-09-12",{"date":77,"type":21},"2026-06-01",{"name":79,"class":80},"Portsmouth Hospitals NHS Trust","OTHER_GOV",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100611786","the-pro-chol-study-100611786","NCT07245108","The Pro-Chol Study","The ProChol Study - Prospective Assessment of Symptoms Following Cholecystectomy in Patients With Symptomatic Uncomplicated Gallstones","ProChol","Inclusion Criteria:\n\n* Ultrasound examination with presence of gallstones and description of size, number and presence of stones in infundibulum or cystic duct\n* Abdominal symptoms believed to be caused by symptomatic uncomplicated gallstones\n* Indication and candidate for elective laparoscopic cholecystectomy\n* Above 18 years of age\n* Ability to give oral and written consent\n* Ability to understand, speak and read Danish\n* Ability to receive digital post\n\nExclusion Criteria:\n\n* History of complicated gallstone disease including acute cholecystitis, pancreatitis, common bile duct stones, or cholangitis\n* Previous sphincterotomy\n* Abnormal liver function test (ALAT\u002FASAT, alkaline phosphatase, bilirubin) without magnetic resonance cholangio-pancreatography or endoscopic ultrasound to rule out common bile duct pathology\n* Indication for urgent cholecystectomy\n* Current pregnancy",{"count":90,"type":21},800,"OBSERVATIONAL","This prospective clinical cohort study will include patients with gallstones and abdominal pain scheduled for surgery (laparoscopic cholecystectomy). Data on quality of life, abdominal pain, gallstone disease, and patient characteristics will be collected before surgery. The outcomes will be assessed three months following surgery and will primarily be determinants for resolution of pain. The aim is to make a prediction score that may aid clinicians and patients in decision making about surgery.",[29,94,95,96],"Gallstone Attack","Uncomplicated Cholelithiasis","Cholecystolithiasis",[98,99,63,67,100],"Cohort study","Prospective clinical study","Pain relief","2025-11-20",{"date":103,"type":38},"2025-11-24",{"date":105,"type":38},"2024-01-22",{"date":107,"type":21},"2027-04",{"name":109,"class":45},"Nordsjaellands Hospital",7,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":55,"minAge":17,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":138,"locationsCount":46},"100587283","prospective-evaluation-of-cornerstone-robotics-sentire-surgical-system-in-major-gastrointestinal-and-urologic-surgery-100587283","NCT06926374","Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery","General Inclusion Criteria for All Procedures:\n\n* Body mass index \\\u003C35 kg\u002Fm2\n* Suitable for the listed minimally invasive surgical procedures for treatment of respective diseases\n* Willingness to participate as demonstrated by giving informed consent\n\nGeneral Exclusion Criteria for All Procedures:\n\n* Contraindication to general anesthesia\n* Severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic intervention\n* Untreated active infection\n* Noncorrectable coagulopathy\n* Presence of another malignancy or distant metastasis\n* Emergency surgery\n* Vulnerable population (e.g., mentally disabled, pregnancy)\n\nRobotic Colorectal Resection\n\nInclusion Criteria:\n\n\\- Adenocarcinoma or large adenoma (not amenable to endoscopic removal) located at the colorectum (from the cecum to the anal verge) amenable to minimally invasive surgery\n\nExclusion Criteria:\n\n* T4 tumor\n* Recurrent tumor\n* Extensive previous abdominal surgery precluding minimally invasive surgery\n\nRobotic Transanal Total Mesorectal Excision\n\nInclusion Criteria:\n\n\\- Mid\u002Flow rectal adenocarcinoma located \\\u003C12 cm from the anal verge\n\nExclusion Criteria:\n\n* T4 tumor or involvement of circumferential resection margin even after neoadjuvant therapy\n* Tumor requiring multivisceral resection\n* Tumor requiring abdominoperineal resection; recurrent rectal tumor\n* T1 tumor that can be treated by local excision\n* Extensive previous abdominal surgery\n\nRobotic Rectopexy\n\nInclusion Criteria:\n\n* Clinically diagnosed with previously untreated and uncomplicated rectal prolapse or enterocele\n\nExclusion Criteria:\n\n\\- Extensive previous abdominal surgery precluding minimally invasive surgery\n\nRadical Prostatectomy\n\nInclusion Criteria:\n\n\\- Clinically diagnosed with nonmetastatic adenocarcinoma of prostate\n\nExclusion Criteria:\n\n\\- Previous history of prostate surgery (e.g., transurethral resection of prostate)\n\nTotal or Partial Nephrectomy\n\nInclusion Criteria:\n\n\\- Clinically diagnosed with nonmetastatic kidney cancer\n\nExclusion Criteria:\n\n* Previous ipsilateral kidney surgery\n* Complex kidney anatomy (e.g., horseshoe kidney, complex renal vascular anatomy)\n\nRadical Cystectomy\n\nInclusion Criteria:\n\n\\- Clinically diagnosed with nonmetastatic bladder cancer\n\nRobotic Esophageal Hiatal Surgery and Fundoplication\n\nInclusion Criteria:\n\n\\- Clinically diagnosed with Hiatal Hernia and \u002F or Gastroesophageal reflux disease amendable to fundoplication\n\nExclusion Criteria:\n\n\\- Previous history of laparotomy precluding minimally invasive surgery\n\nRobotic Gastrectomy\n\nInclusion Criteria:\n\n\\- Clinical diagnosis of gastric tumor (Adenocarcinoma or Gastrointestinal Stromal Tumor (GIST)) amendable to minimally invasive radical gastrectomy\n\nExclusion Criteria:\n\n\\- Previous history of laparotomy precluding minimally invasive surgery\n\nRobotic Esophagectomy\n\nInclusion Criteria:\n\n\\- Clinical diagnosis of carcinoma of esophagus amendable to minimally invasive esophagectomy\n\nExclusion Criteria:\n\n\\- Esophageal carcinoma after definitive chemoradiotherapy and indicated for salvage esophagectomy\n\nRobotic Cholecystectomy\n\nInclusion Criteria:\n\n\\- Symptomatic gallbladder stones clinically indicated for laparoscopic cholecystectomy\n\nExclusion Criteria:\n\n* Acute cholecystitis\n* Previous history of abdominal surgery","80 Years",{"count":119,"type":21},90,[24],"Robotic assisted surgery has been performed for more than two decades with good success and safety profile. However, there was only one dominating robotic surgical system available in the past which led to high cost for robotic surgery. Recently, a new robotic surgical system (Sentire Robotic Surgical System) was introduced by researchers of The Chinese University of Hong Kong (CUHK). This new robotic surgical system aims to achieve similar outcomes and standards of robotic surgery performed using the dominating system but with a significantly lower cost. The technologic innovation and development of this new robotic system is made by the Cornerstone Robotics Limited, which is based in Hong Kong. In a pilot clinical study conducted at Prince of Wales Hospital involving 55 patients, the Sentire Robotic Surgical System had demonstrated high success rate with minimal complications in patients who underwent robotic colorectal, upper gastrointestinal, and urologic surgery. Researchers of CUHK would therefore like to conduct another prospective study to further evaluate the efficacy and safety of Sentire Surgical System C1000 in major gastrointestinal and urologic surgery with expanded indications. It is believed that the results of this study will provide data to support its use for wide range of procedures with minimal access trauma, for the benefit of patients. This system will also lead to a wider range of clinical application for minimally invasive surgery with a cost-effective model.",[123,124,125,126,127,128,129,130,29,131],"Colorectal Carcinoma","Rectal Prolapse","Prostate Cancer (Adenocarcinoma)","Bladder Cancer","Kidney Cancer","Hiatal Hernia With Gastroesophageal Reflux Disease","GIST - Gastrointestinal Stromal Tumor","Esophageal Cancer","Gastric Cancer","2025-04-11",{"date":134,"type":38},"2025-04-16",{"date":136,"type":38},"2025-03-25",{"date":107,"type":21},{"name":139,"class":45},"Chinese University of Hong Kong"]